Mismatch Repair Deficiency clinical trials at UC Irvine
1 research study open to eligible people
open to eligible people ages 18 years and up
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Orange, California and other locations
Our lead scientists for Mismatch Repair Deficiency research studies include John Fruehauf, MD.